RU1822780C - Method of blood coagulability decrease - Google Patents
Method of blood coagulability decreaseInfo
- Publication number
- RU1822780C RU1822780C SU894696441A SU4696441A RU1822780C RU 1822780 C RU1822780 C RU 1822780C SU 894696441 A SU894696441 A SU 894696441A SU 4696441 A SU4696441 A SU 4696441A RU 1822780 C RU1822780 C RU 1822780C
- Authority
- RU
- Russia
- Prior art keywords
- heparin
- decrease
- time
- minutes
- blood coagulability
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 6
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002897 heparin Drugs 0.000 claims abstract description 15
- 229920000669 heparin Polymers 0.000 claims abstract description 15
- 230000015271 coagulation Effects 0.000 claims description 4
- 238000005345 coagulation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к медицине, в частности к гематологии. Цель - повышение эффективности способа. В результате пр мое антикоагул ционное действие гепарина повышаетс в два с лишним раза. Дл этого гепарин предварительно облучают ультрафиолетовым светом в дозе 1-4 Дж/л.The invention relates to medicine, in particular to hematology. The goal is to increase the efficiency of the method. As a result, the direct anticoagulant effect of heparin is doubled. For this, heparin is pre-irradiated with ultraviolet light at a dose of 1-4 J / L.
Description
Изобретение относитс к медицине и может быть использовано дл свертываемости крови при лечении гиперкоагул цинных состо ний.The invention relates to medicine and can be used for blood coagulation in the treatment of hypercoagulant conditions.
Цель - повышение эффективности способа .The goal is to increase the efficiency of the method.
Дл этого перед введением в организм больного коммерческий лекарственный препарат гепарина облучают ультрафиолетовым светом в дозе 1-4 Дж/л.To this end, a commercial drug of heparin is irradiated with ultraviolet light at a dose of 1-4 J / L before being introduced into the patient.
Способ по сн етс следующими примерами .The method is illustrated by the following examples.
Пример 1. Больному К-ву В.А.. 60 лет, и/б № 6052, после операции по поводу острого холецистита ввели 5000 ЕД гепарина. Через 20 мин после введени гепарина врем свертывани крови у больного равн лась 14.3 мин, врем рекальцификации плазмы 236 с, тромбиновое врем 75 с. Через 5 ч показатели возвратились к исходному уровню . После этого больному ввели 5000 ЕД гепарина из того же флакона, предварительно облученного ультрафиолетовым светом в дозе 1 Дж/л. Через 20 мин после введени облученного гепарина врем свертывани крови, врем рекальцификации плазмы и тромбиновое врем составили соответственно 18,5 мин. 315 с и 108 с, т.е. соответственно на 29%, 33% и44% больше, чем после введени необлученного гепарина.Example 1. Patient K-vu V.A. 60 years old, and / b No. 6052, after surgery for acute cholecystitis, 5000 IU of heparin was administered. 20 minutes after heparin was administered, the coagulation time of the patient was 14.3 minutes, the plasma recalcification time was 236 s, and the thrombin time was 75 s. After 5 hours, the indicators returned to their original level. After that, the patient was injected with 5000 IU of heparin from the same bottle, previously irradiated with ultraviolet light at a dose of 1 J / L. 20 minutes after the administration of irradiated heparin, the coagulation time, plasma recalcification time, and thrombin time were 18.5 minutes, respectively. 315 s and 108 s, i.e. respectively 29%, 33% and 44% more than after administration of unirradiated heparin.
Пример 2. Больной Смирновой A.M., 64 лет, и/Ь № 6130, 27.03.88 г. после операции по поводу острой кишечной непроходимости ввели 5000 ЕД гепарина. Через 20 мин после введени гепарина врем свертывани крови у больной равн лось 16,5 мин, врем рекальцификации плазмы - 285 с, тромбиновое врем - 89 с. Через 6 часов показатели возвратились к исходному уровню . После этого больной ввели 5000 ЕД из того же флакона, предварительно облученного ультрафиолетовым светом в дозе 2,5 Дж/л. Через 20 мин после введени облученного гепарина врем свертывани крови , врем рекальцификации плазмы и тромбиновое врем составили соответственно 20 мин, 320 си 145 с, т.е. на соответственно 39%, 12 и 63% больше, чем после введени необлученного гепарина.Example 2. Patient Smirnova A.M., 64 years old, and / b No. 6130, 03/27/88, after surgery for acute intestinal obstruction, introduced 5000 UNITS of heparin. 20 minutes after heparin was administered, the coagulation time of the patient was 16.5 minutes, the plasma recalcification time was 285 s, and the thrombin time was 89 s. After 6 hours, the indicators returned to their original level. After this, the patient was administered 5000 units from the same vial, previously irradiated with ultraviolet light at a dose of 2.5 J / L. 20 minutes after the administration of irradiated heparin, the blood coagulation time, plasma recalcification time, and thrombin time were 20 minutes, 320 si, 145 s, respectively. 39%, 12 and 63% respectively more than after administration of unirradiated heparin.
Положительный эффект изобретени заключаетс в повышении эффективности снижени свертываемости крови по сравнению с прототипом на 33-57% (по отдельным показател м свертываемости крови) за счет повышени противосвертывающей активности гепарина.The positive effect of the invention is to increase the efficiency of reducing blood coagulation compared to the prototype by 33-57% (according to individual indicators of blood coagulation) by increasing the anticoagulant activity of heparin.
(/(/
СWITH
0000
ю го VIyu vi
0000
оabout
318227804318227804
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894696441A RU1822780C (en) | 1989-05-29 | 1989-05-29 | Method of blood coagulability decrease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU894696441A RU1822780C (en) | 1989-05-29 | 1989-05-29 | Method of blood coagulability decrease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU1822780C true RU1822780C (en) | 1993-06-23 |
Family
ID=21450001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894696441A RU1822780C (en) | 1989-05-29 | 1989-05-29 | Method of blood coagulability decrease |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU1822780C (en) |
-
1989
- 1989-05-29 RU SU894696441A patent/RU1822780C/en active
Non-Patent Citations (1)
| Title |
|---|
| Кузин М.И. Актуальные проблемы/емо- стазиологии. 2-е изд., М., 1981, с. 362. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68908913T2 (en) | Factor XIII for the prevention of intraventricular bleeding. | |
| RU1822780C (en) | Method of blood coagulability decrease | |
| KR100255095B1 (en) | Therapeutic agent for threatened abortion | |
| RU2095067C1 (en) | Method of stimulation of repair and trophic processes in organism tissues | |
| RU2223727C2 (en) | Method for treating the cases of erosions and ulcers of the cornea persisting for a long time | |
| DE69113437T2 (en) | Therapeutic agents for diabetic gangrene. | |
| CA1322168C (en) | Process for the remission of the symptoms associated with aids | |
| EP0213072B1 (en) | Treatment of chronic imflammatory disease | |
| RU95113855A (en) | METHOD FOR CONSERVATIVE TREATMENT OF EYE BURNS | |
| CN1488399A (en) | Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease | |
| SU1169655A1 (en) | Method of treatment of thrombolytic diseases of the artery of the extremities | |
| RU2092107C1 (en) | Method for treatment hepatic insufficiency in patients affected with ascites | |
| SU1076118A1 (en) | Method of treatment of alveolitis | |
| RU2147841C1 (en) | Method for treating the cases of laryngeal papillomatosis | |
| RU2078595C1 (en) | Method for treatment of hepatic insufficiency | |
| RU2063737C1 (en) | Method for correcting leukopenia in cases of acute lymphoblastous leukoses in children | |
| SU1697828A1 (en) | Method for curing the type b acute viral hepatitis | |
| CN1067247C (en) | Sodium alginate diester for preventing and curing thrombocytopenia and leukopenia | |
| EP0565722A1 (en) | Pharmaceutical preparation for pernasal administration | |
| RU2070058C1 (en) | Method of chronic bronchitis treatment | |
| SU1666116A1 (en) | Method for treatment of trifacial neuralgia | |
| EP1786455A2 (en) | Use of intradiscally administered autologous cells producing type i interferon for the treatment of degenerative disc disease | |
| RU2063774C1 (en) | Method for treating the cases of chronic blood circulation disorders | |
| RU2014020C1 (en) | Method of treating styloiditis | |
| Didisheim et al. | Studies on thrombus prevention in an extracorporeal arteriovenous microshunt |